论文部分内容阅读
[目的]观察吉西他滨单药治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效和毒性反应。[方法]46例Ⅲ～Ⅳ期NSCLC患者均经病理组织学或细胞学检查确诊。国产吉西他滨(泽菲)1000mg/m2,静滴,d1、8,每3～4周重复,2个周期后CT评价疗效。[结果]46例患者均可评价疗效,无CR,PR12例,有效率26.0%,中位生存期7.1个月,中位疾病进展时间(TTP)6.2个月,1年生存率32.5%。主要的毒副反应为白细胞及血小板降低,均可耐受。[结论]吉西他滨单药治疗老年晚期NSCLC疗效确切,可明显改善患者生存质量,延长生存时间,毒副反应轻。
[Objective] To observe the clinical efficacy and toxicity of gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). [Method] 46 cases of stage Ⅲ ~ Ⅳ NSCLC patients were diagnosed by histopathology or cytology. Domestic gemcitabine (Zephyr) 1000mg / m2, intravenous infusion, d1,8, repeated every 3 to 4 weeks, 2 cycles after the evaluation of CT. [Results] All of the 46 patients could evaluate the curative effect. There were 12 cases without CR and PR, the effective rate was 26.0%, the median survival time was 7.1 months, the median time to progression (TTP) was 6.2 months, and the 1-year survival rate was 32.5%. The main side effects of leukopenia and thrombocytopenia can be tolerated. [Conclusion] Gemcitabine monotherapy is effective in treating elderly patients with advanced NSCLC, which can significantly improve the quality of life, prolong the survival time and reduce the toxic and side effects.